Why the study?
Oncohypertension is a relatively recent concept, and this review aims to provide an overview of its pathophysiology, clinical implications, diagnostic approaches, and management strategies.
This review highlights the emerging concept of oncohypertension, detailing its pathophysiology, diagnosis, and multidisciplinary management strategies.
Alerts clinicians to tumor-driven hypertension in cancer patients; extends the oncohypertension concept but leaves open prospective validation.
Oncohypertension is a relatively recent concept that refers to the development of elevated blood pressure in patients with cancer, which is driven by the tumor itself. This review article aims to provide an overview of oncohypertension, including its pathophysiology, clinical implications, diagnostic approaches, and management strategies. The study discusses the association between oncological disorders and hypertension, highlighting the underlying mechanisms responsible for the development of oncohypertension. Furthermore, various diagnostic methods, including imaging techniques and laboratory tests, are discussed in detail. Finally, treatment options for oncohypertension, including both pharmacological and non-pharmacological approaches, are thoroughly reviewed to optimize blood pressure control and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Tajdini et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: